NCI Precision Medicine Study Hones in on Cancer Remission
Researchers say a non-chemotherapy treatment is causing more cancer patients to experience full remission.
A recent National Cancer Institute study shows that a new targeted therapy can help prolong the time cancer patients are in remission. Called the ViPOR regimen, the non-chemotherapy treatment shrinks tumors of those who suffer from B-cell lymphoma.
Dr. Christopher Melani, associate research physician with the Lymphoid Malignancies Branch in the Center for Cancer Research at NCI, highlights the importance of combining five therapies and administering them during a fixed cycle to maximize drug synergy and make tumors disappear.
He also shares details about the second phase of the study that is expected to take place later this year as well as how precision medicine could potentially lead to a cure for all types of cancer.
-
Dr. Christopher Melani Associate Research Physician, Lymphoid Malignancies Branch, Center for Cancer Research NCI
-
FDA Outlines Future Tech Priorities
FDA is advancing its tech capabilities with quantum computing, zero-trust architecture and modernized data sharing.
6m read -
Quantum, Workforce Issues Lead FDA’s Digital Transformation
The FDA is taking a proactive approach to its digital transformation efforts that its tech leaders highlighted in a new IT strategy.
14m listen -
Storytelling Miniseries: The Skill that Can Unite Cross-Generational Teams
The third episode in this Storytelling Miniseries for federal leaders discusses bridging gaps across generations in the workplace.
20m listen -
HHS to Launch 2 Acquisition Programs in FY 2025
The two programs will streamline knowledge and foster two-way communication between industry and the agency.
2m read
